Exclusive industry funding		Partial or exclusive industry funding
State	n / vs. total	Incremental effect	n / vs. total	Incremental effect
Alzheimer’s: mild, independent living	6 / 32	0.002 (−0.12 to 0.124)	13 / 32	0.002 (−0.12 to 0.124)
Alzheimer’s: severe, not independent	16 / 61	0.04 (−0.062 to 0.141)	33 / 61	0.04 (−0.062 to 0.141)
Breast cancer: progression-free / early stage	30 / 197	−0.028 (−0.073 to 0.017)	67 / 197	−0.025 (−0.069 to 0.018)
Breast cancer: progressive / late stage	65 / 292	0.015 (−0.029 to 0.059)	136 / 292	0.017 (−0.026 to 0.061)
CVA: mild (Rankin 0–1)	41 / 205	0.051 (−0.022 to 0.124)	97 / 205	0.051 (−0.023 to 0.124)
CVA: moderate (Rankin 2–3)	28 / 163	−0.023 (−0.086 to 0.04)	68 / 163	−0.009 (−0.072 to 0.055)
CVA: severe (Rankin 4–5)	34 / 188	0.01 (−0.066 to 0.087)	81 /188	0.031 (−0.047 to 0.11)
COPD: mild to moderate	23 / 97	−0.029 (−0.072 to 0.015)	50 / 97	−0.029 (−0.072 to 0.014)
COPD: severe to very severe	30 / 121	0.002 (−0.054 to 0.058)	68 / 121	0.009 (−0.047 to 0.064)
COPD: exacerbation	24 / 99	0.047 (−0.003 to 0.097)	52 / 99	0.058 (0.009 to 0.106)
Colorectal cancer: progression-free / early stage	4 / 53	0.002 (−0.103 to 0.106)	10 / 53	−0.008 (−0.107 to 0.09)
Colorectal cancer: progressive / late stage	8 / 79	0.026 (−0.071 to 0.124)	19 / 79	−0.007 (−0.097 to 0.084)
Diabetes w/o complications	16 / 109	−0.009 (−0.045 to 0.028)	45 / 109	0.001 (−0.035 to 0.036)
Diabetes w/ amputation	18 / 87	−0.005 (−0.05 to 0.041)	43 / 87	0.015 (−0.029 to 0.058)
Diabetes w/ dialysis	20 / 91	0.022 (−0.055 to 0.099)	51 / 91	0.031 (−0.047 to 0.108)
Diabetes w/ peripheral neuropathy	24 / 108	−0.013 (−0.11 to 0.085)	58 / 108	−0.004 (−0.105 to 0.097)
Diabetes w/ vision loss	13 / 85	−0.063 (−0.137 to 0.011)	38 / 85	−0.02 (−0.099 to 0.058)
Hepatitis B: chronic infection	18 / 101	0.052 (−0.017 to 0.122)	39 / 101	0.059 (−0.01 to 0.129)
Hepatitis C: chronic infection	53 / 293	0 (−0.053 to 0.053)	124 / 293	0.011 (−0.041 to 0.063)
Compensated cirrhosis	48 / 293	−0.008 (−0.065 to 0.049)	121 / 293	0.004 (−0.05 to 0.058)
Decompensated cirrhosis	39 / 262	0.001 (−0.031 to 0.033)	100 / 262	0.018 (−0.013 to 0.049)
Prior liver transplant (<1 year)	28 / 159	0.021 (−0.053 to 0.094)	71 /159	0.024 (−0.045 to 0.093)
Prior liver transplant (>1 year)	22 / 124	−0.016 (−0.087 to 0.055)	54 / 124	−0.01 (−0.078 to 0.059)
Stable angina	6 / 47	−0.051 (−0.204 to 0.102)	17 / 47	−0.051 (−0.204 to 0.102)
Unstable angina	4 / 47	−0.049 (−0.191 to 0.092)	16 / 47	−0.063 (−0.193 to 0.066)
Past M.I. (<1 year)	23 / 146	0.017 (−0.033 to 0.067)	61 / 146	0.02 (−0.029 to 0.07)
Past M.I. (>1 year)	21 / 106	−0.056 (−0.111 to −0.002)	49 / 106	−0.036 (−0.089 to 0.017)
Lung cancer: progression-free / early stage	6 / 95	−0.031 (−0.087 to 0.026)	23 / 95	−0.003 (−0.059 to 0.052)
Lung cancer: progressive / late stage	10 / 123	−0.037 (−0.092 to 0.018)	30 / 123	−0.044 (−0.099 to 0.01)
Major depressive order: moderate	4 / 24	−0.065 (−0.139 to 0.008)	8 / 24	−0.065 (−0.139 to 0.008)
Major depressive order: severe	4 / 33	−0.026 (−0.111 to 0.06)	9 / 33	−0.027 (−0.111 to 0.057)